Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

September 17, 2025

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

September 16, 2025

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

September 2, 2025

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

August 28, 2025

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

August 14, 2025

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

July 23, 2025

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

July 15, 2025

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

June 24, 2025

Enveric Biosciences Announces Participation in 2025 BIO International Convention

June 16, 2025

‹
1
2
3
4
…
17
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.